MacroGenics to Participate in Upcoming Investor Conference
May 19, 2021 07:00 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, May 19, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics Provides Update on Corporate Progress and First Quarter 2021 Financial Results
April 29, 2021 16:01 ET
|
MacroGenics, Inc.
MARGENZA™ launched in mid-March Upcoming poster presentation of MGC018 initial Phase 1 clinical data at ASCOConference call scheduled for today at 4:30 p.m. ET. ROCKVILLE, Md., April 29, 2021 ...
MacroGenics Announces Date of First Quarter 2021 Financial Results Conference Call
April 19, 2021 16:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, April 19, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics Announces Presentations at the 2021 AACR Annual Meeting
April 10, 2021 08:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, April 10, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics to Participate in Upcoming Investor Conferences
February 26, 2021 07:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Feb. 26, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics Provides Update on Corporate Progress and 2020 Financial Results
February 25, 2021 16:01 ET
|
MacroGenics, Inc.
MARGENZA™ approved in December 2020; commercial launch expected March 2021July 2021 PDUFA target action dates for partnered products retifanlimab and teplizumabMultiple clinical updates across...
MacroGenics Announces Date of Fourth Quarter and Full Year 2020 Financial Results Conference Call
February 18, 2021 16:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Feb. 18, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics Names Federica O’Brien to its Board of Directors
February 11, 2021 16:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Feb. 11, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics Announces Achievement of $10 Million Milestone Related to Retifanlimab Collaboration with Incyte
February 11, 2021 07:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Feb. 11, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics to Participate in Upcoming Investor Conferences
February 08, 2021 07:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Feb. 08, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...